The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-arm phase ib/II study of durvalumab and guadecitabine in advanced kidney cancer (NCT03308396).
 
Sarah Elizabeth Yentz
No Relationships to Disclose
 
Melissa Andrea Reimers
No Relationships to Disclose
 
Monika Joshi
Consulting or Advisory Role - Bayer
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Castle Biosciences; Eisai; Exelixis; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Newlink Genetics
 
Shilpa Gupta
Consulting or Advisory Role - Exelixis; Genentech; Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Pfizer
Research Funding - Astellas Medivation (Inst); Innocrin Pharma (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst)
 
Eric A. Singer
No Relationships to Disclose
 
Stephanie Daignault
No Relationships to Disclose
 
Weiping Zou
No Relationships to Disclose
 
Dana Musapatika
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)